Discovery and clinical introduction of first-in-class imipridone ONC201

ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC2...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2016
נושאים:
Review
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342060/
https://ncbi.nlm.nih.gov/pubmed/27602582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11814
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים